Pilot in vivo studies showed a significant inhibition of tumor growth when Y537S ESR1 xenograft tumors were treated with T6I-29-1A, with more significant anti-tumoral effects observed in the I.P. pilot study. Here, ESR1 is linked to neoplasm.